Iowa SF433 eliminates prior authorization for direct acting antiviral medications on the Medicaid preferred drug list and mandates a review of Vosevi.

Iowa SF433 modifies the requirements for direct acting antiviral medications under Medicaid. It prohibits the Department of Health and Human Services from requiring prior authorization for these medications if they are on the preferred drug list. Additionally, the Iowa Medical Assistance Drug Utilization Review Commission is tasked with reviewing the prescription drug Vosevi for potential inclusion on the preferred drug formulary by July 1, 2026. This review is to determine if Vosevi should be classified as a preferred direct acting antiviral for hepatitis C treatment.

Iowa SF433 eliminates prior authorization for direct acting antiviral medications on the Medicaid preferred drug list and mandates a review of Vosevi.

Iowa SF433 modifies the requirements for direct acting antiviral medications under Medicaid. It prohibits the Department of Health and Human Services from requiring prior authorization for these medications if they are on the preferred drug list. Additionally, the Iowa Medical Assistance Drug Utilization Review Commission is tasked with reviewing the prescription drug Vosevi for potential inclusion on the preferred drug formulary by July 1, 2026. This review is to determine if Vosevi should be classified as a preferred direct acting antiviral for hepatitis C treatment.